Schizophrenia Clinical Trial
Official title:
The Improving Care and Reducing Cost (ICRC) Program
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers.
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease
management and the overall process of care in treating the chronic illness schizophrenia in
order to reduce ER visits and hospital days while providing better care, better health and
increased patient satisfaction. This will be done by fostering innovation in the use of
technology and by training and deploying a new cadre of personnel in the behavioral health
field: Mental Health/Health Technology (MH/HT) Case Managers. The specific treatments we
propose to use are evidence based, but their dissemination has been limited because of lack
of trained personnel and cost. The model we propose, the Health Technology Program (HTP),
will address these problems through use of the web and mobile phone based training and
interventions.
The components of the HTP program that are being tested in the pilot program include: 1)
evidence-based pharmacological treatment facilitated by a web-based prescriber decision
support system-Prescriber Decision Assistant (PDA) 2) brief, in-person, relapse prevention
counseling with supplemental web-based learning modules, 3) a daily support website that
offers web- and phone-based resources to support persons with schizophrenia and their family
members or others. The resources include a patient and family Psycho-Education Treatment
program, which includes electronic peer groups facilitated by mental health professionals,
providing medication reminders via web and phone, and conducting monitoring of early warning
signs of relapse via web and phone 4) an interactive smart phone text-messaging application
to support medication adherence, facilitate coping with symptoms and improve daily
functioning in individuals with schizophrenia 5) a web-based, self-administered
cognitive-behavioral therapy (CBT) program for the management of hallucinations. All
patients will be provided with pharmacological treatment (PDA), brief in-person relapse
prevention counseling, and an Android mobile phone. The other program components will be
provided to patients using a shared decision-making approach to assess need and preference.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |